Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance LifesciencesBOM:543064 -0.07%87 PB Ratio is 4.16 as of Aug. 02, 2026, which is 50% below its 10-year median of 8.32. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 923 Drug Manufacturers companies, Cohance Lifesciences ranks worse than 77.9% on this metric.
The historical rank and industry rank for Cohance Lifesciences's PB Ratio or its related term are showing as below:
BOM:543064'
s PB Ratio Range Over the Past 10 Years
Min: 3.01 Med: 8.32 Max: 17.52
Current: 4.21
During the past 8 years, Cohance Lifesciences's highest PB Ratio was 17.52. The lowest was 3.01. And the median was 8.32.
BOM:543064's PB Ratio is ranked worse than 77.9% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.88
vs BOM:543064: 4.21
During the past 12 months, Cohance Lifesciences's average Book Value Per Share Growth Rate was 53.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Cohance Lifesciences was 37.30% per year. The lowest was 3.60% per year. And the median was 20.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cohance Lifesciences PB Ratio Related Terms
Cohance Lifesciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cohance Lifesciences (BOM:543064) has a PB Ratio of 4.16 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cohance Lifesciences and its competitors. This is 50% below median its historical median of 8.32. Over the past decade, Cohance Lifesciences' PB Ratio has ranged from 3.01 to 17.52. According to the industry distribution chart, Cohance Lifesciences ranks #719 out of 923 companies in the Drug Manufacturers industry, placing it in the top 77.9%.
Is Cohance Lifesciences' PB Ratio too high?
Cohance Lifesciences' current PB Ratio of 4.16 is 50% below median its 10-year median of 8.32. Over the past 10 years, this metric has ranged from a low of 3.01 to a high of 17.52. The Drug Manufacturers industry median PB Ratio is 1.88. Cohance Lifesciences' value of 4.16 is 121.3% above this industry median. Based on the distribution chart, Cohance Lifesciences ranks #719 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #719 out of 923 companies for PB Ratio. This places Cohance Lifesciences in the lower half of its industry. The industry median PB Ratio is 1.88. Cohance Lifesciences' value of 4.16 is 121.3% above this benchmark. Historically, Cohance Lifesciences' own PB Ratio has ranged from 3.01 to 17.52 over the past decade. While the company's 10-year median is 8.32 vs. the industry median of 1.88, Cohance Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current PB Ratio of 4.16 is 121.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current PB Ratio is 4.16, which is 50% below median its own 10-year median of 8.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current PB Ratio is 4.16, which is 50% below median its 10-year median of 8.32 and 121.3% above the Drug Manufacturers industry median of 1.88. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current PB Ratio is 4.16 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
PB Ratio: 4.16 (50% below median its 10-year median of 8.32)
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
Industry Position: 121.3% above the Drug Manufacturers median (#719 of 923)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
